Labitad, Rhen Heart L.
HRN: 21-93-90 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/21/2024
OXACILLIN 500MG (VIAL)
07/21/2024
07/27/2024
IV
395mg
Q6
Impetigo
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes